Kyriakos P. Papadopoulos, MD

Co-Director of Clinical Research, Co-Founder of START

Publications
475 +
Clinical Trials Conducted
100 +

Dr. Kyriakos P. Papadopoulos is the Co-Director of Clinical Research at START in San Antonio, Texas. He is board-certified in Internal Medicine, Medical Oncology & Hematology. His clinical interests include drug development and malignancies of the upper gastrointestinal-tract and lungs. Dr. Papadopoulos completed his MBBCh and MSc (Med) at the University of Witwatersrand, Johannesburg, and his specialty training in Internal Medicine at Groote Schuur Hospital, Cape Town, South Africa. He followed this with a fellowship in Medical Oncology and Hematology at the College of Physicians and Surgeons of Columbia University, NY. He served as the Florence Irving Assistant Professor of Medicine at the College of Physicians and Surgeons of Columbia University, where he was co-director of the GI and Lung Tumor Clinic.

Dr. Papadopoulos was appointed Clinical Associate Professor of Medicine, University of Texas Health Science Center at San Antonio. A senior clinical investigator at the Cancer Therapy & Research Center’s (CTRC) Institute for Drug Development, San Antonio, TX , he was also a member of the CTRC’s Medical Executive Committee before his departure to co-found START. He received a Career Development Award from the National Institute of Health, as well as the Anna-Maria Kellen Clinical Investigator Award of the Cancer Research Institute for immunotherapy research. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research and a Fellow of the College of Physicians of South Africa.

Areas of Expertise

Lung Cancer

Liver Cancer

Upper GI Cancer

In The Press

By:

Journal: Clin Cancer Res.

Published Date: May 14, 2015

By:

Journal: Clin Cancer Res.

Published Date: May 14, 2015

By:

Journal: Cancer Discovery

Published Date: May 23, 2016

By:

Journal: Journal of Clinical Oncology

Published Date: April 20, 2019